China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
18.92
+0.13 (0.69%)
May 13, 2025, 3:00 PM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 3.08B CNY in the quarter ending March 31, 2025, with 8.58% growth. This brings the company's revenue in the last twelve months to 11.15B, down -4.59% year-over-year. In the year 2024, China Resources Double-Crane Pharmaceutical had annual revenue of 11.21B, down -0.87%.
Revenue (ttm)
11.15B
Revenue Growth
-4.59%
P/S Ratio
1.74
Revenue / Employee
830.88K
Employees
13,414
Market Cap
19.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
Dec 31, 2020 | 8.50B | -877.05M | -9.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Sichuan Biokin Pharmaceutical | 5.82B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |